New York-based Coronado Biosciences has registered to become a public reporting company through a Form 10. Coronado is developing immunotherapy approaches to treat acute myeloid leukemia and autoimmune diseases such as multiple sclerosis and inflammatory bowel disease. Coronado is preparing to start a Phase 2 trial of one of its experimental molecules in Crohn’s Disease early next year. The company raised $25.8 million in venture funding earlier this month, led by National Securities Corporation. It previously raised $21.6 million last November.
By posting a comment, you agree to our terms and conditions.